Search Results
Dec 02, 2025, 16:05 ET ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Dec 02, 2025, 11:00 ET Harness Announces New Integrations with AWS to Connect AI Software Development with Intelligent Delivery
system:Integration of Harness's Model Context Protocol (MCP) Server with Kiro, allowing developers to manage and troubleshoot CI/CD pipelines, understand security issues, list and run chaos engineering experiments, and analyze cloud cost directly from their AWS environments by using
More news about: Harness
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
a high-affinity anti-CD123 antibody and an indolinobenzodiazepine pseudodimer (IGN) payload. An oral presentation will showcase data from the dose expansion part of an open-label Phase 1b/2 study of PVEK combined with venetoclax and azacitidine (VEN + AZA) in newly diagnosed, CD123-positive AML patients
More news about: AbbVie Inc.
Dec 02, 2025, 07:00 ET Keeper Named an Overall Leader in KuppingerCole's Leadership Compass Report for Non-Human Identity Management
control for these identities, eliminating hardcoded credentials and unmanaged secrets that often reside in infrastructure-as-code repositories and CI/CD pipelines.Keeper's architecture enables secrets to be programmatically managed and rotated based on identity, policy and runtime context, ensuring
More news about: Keeper Security
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™,
More news about: Antengene Corporation Limited
Dec 01, 2025, 16:13 ET BreachLock Named a Leader in 2025 GigaOm Radar Report for Penetration Testing as a Service (PTaaS) for Third Consecutive Year
Ray, author of the GigaOm Radar Report for PTaaS, highlighted BreachLock's strengths in the report, writing, "BreachLock excels for enterprises with CI/CD pipelines requiring continuous security validation through its deep SDLC integration, risk-contextualized findings, and pipeline security gates. Its
More news about: BreachLock
Dec 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Dec 01, 2025, 10:17 ET OncoPrecision anuncia la presentación oral de ONC001, un ADC dirigido a CD64 para la leucemia monocítica
- OncoPrecision anuncia la presentación oral de ONC001, un ADC dirigido a CD64 de primera clase para la leucemia monocítica, en la 67ª Reunión Anual de la ASHNUEVA YORK, 1 de diciembre de 2025 /PRNewswire/ --
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including highly resistant subsets. The ADC was developed
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including highly resistant subsets. The ADC was developed
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision gibt an, dass es auf der 67. ASH-Jahrestagung eine mündliche Präsentation zu ONC001, einem erstklassigen CD64-gerichteten ADC für monozytäre Leukämie, durchführen wird
ONC001 ist ein neuartiges Antikörper-Wirkstoff-Konjugat (ADC), das speziell auf CD64 abzielt, einen myeloischen Rezeptor, der bei CMML und akuter myeloischer Leukämie vom Typ M4/M5, einschließlich hochresistenter Subtypen, weit verbreitet
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET Lors de la 67e réunion annuelle de l'ASH, OncoPrecision a annoncé la présentation orale de ONC001, un conjugué anticorps-médicament ciblant le récepteur CD64, premier de sa catégorie, pour la leucémie monocytaire.
ONC001 est un conjugué anticorps-médicament (ADC), premier de sa catégorie, conçu pour cibler de manière unique le CD64, un récepteur limité aux myéloïdes et omniprésent dans la leucémie myélomonocytaire chronique et la leucémie myéloïde aiguë M4/M5, y compris dans les
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:01 ET Singer/Songwriter Sydney Irving releases new music video for "Something Better" from acclaimed album UNFASHIONED CREATURES on DEKO Entertainment / Warner Music Group - ADA
PURCHASE THE CD OF UNFASHIONED CREATURES BY SYDNEY IRVING As we continue to expand our roster and introduce people to great new music by young artists,
More news about: PILATO ENTERTAINMENT MARKETING & MEDIA LLC
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 08:05 ET Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Added to Express Scripts National Commercial Formularies
who are candidates for phototherapy or systemic therapyactive psoriatic arthritis (PsA)moderately to severely active Crohn's disease (CD)moderately to severely active ulcerative colitisPediatric patients 6 years and older with:moderate
More news about: Accord BioPharma
Dec 01, 2025, 08:00 ET Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Nov 30, 2025, 08:00 ET Avandra Acquires DatCard Systems and Sorna Corporation to Create World's Largest Medical Imaging Platform to Support Patient Care and Breakthrough Medical Research
over twenty-five years. Sorna's flagship Vertex Platform is a comprehensive suite of applications including cloud-brokered data sharing, automated DICOM CD production, and intelligent routing of patient data. Collectively, DatCard and Sorna serve the majority of Academic Medical Centers in the United
More news about: Avandra
Nov 28, 2025, 00:00 ET Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
conducted exclusively in China at premier CAR-T clinical centers. The approach utilizes Imugene's CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies—a transformative "mark and kill" strategy."This collaboration allows us to validate
More news about: Imugene Ltd
Nov 27, 2025, 06:30 ET Intratumoral Cancer Therapies Market to Reach USD 630.7 Million by 2033 as Next-Generation Localized Immunotherapies Transform Solid Tumor Treatment
2033 - CAGR 16.5%.CD Antigen Cancer Therapy Market Size to Grow from US$27.5 B in 2024 to US$54.05 B by 2035.About DataM IntelligenceDataM
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 05:23 ET IFS Cloud 25R2: Unlocking 10X Industrial Workforce Capacity with Digital Workers and Applied Industrial AI
https://mb.cision.com/Public/855/4273633/8d47cd6512531b00_org.png930x432px PRESS
More news about: IFS
Nov 27, 2025, 05:21 ET IFS Cloud 25R2: Unlocking 10X Industrial Workforce Capacity with Digital Workers and Applied Industrial AI
https://mb.cision.com/Public/855/4273633/8d47cd6512531b00_org.png930x432px PRESS
More news about: IFS
Nov 26, 2025, 05:28 ET Il Gruppo Menarini annuncia che, al 67° Congresso Annuale dell'American Society of Hematology, presenterà nuovi dati su ELZONRIS® (tagraxofusp-erzs)
60-70 anni. Una caratteristica fondamentale delle cellule tumorali BPDCN è l'elevata espressione di una proteina chiamata CD123, osservabile sulla superficie delle cellule. Ciò rende il CD123 un marcatore diagnostico cruciale nonché un bersaglio primario per terapie di precisione volte a colpire direttamente
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 26, 2025, 01:48 ET Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD)Findings support the therapeutic potential of ZYMFENTRA
More news about: Celltrion
Nov 25, 2025, 19:10 ET Menarini Group、ELZONRIS®（タグラクソフスプ・エルツ）の新たなデータを第67回米国血液学会年次総会・学術展示会で発表
他CD123陽性の再発または難治性急性骨髄性白血病に対するタグラクソフスプと低強度化学療法による治療*（Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia*）
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
models, IVT-8086 induces multiple antitumor effects, including potent reduction in tumor burden in primary and metastatic tumors, reduced expression of CD38 and PD-1 in tumor-infiltrating lymphocytes (TILs), inhibition of angiogenesis, and increased interferon gamma (IFNγ) in tumor-associated macrophages
More news about: Innova Therapeutics